Institutional investors hold a majority ownership of BIIB through the 89.75% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2016, these large investors purchased a net $1.4 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
WELLINGTON MANAGEMENT CO. LLP Bought 1.3 Million shares of Biogen
UBS ASSET MANAGEMENT (AMERICAS) ... Bought 1.2 Million shares of Biogen
T. ROWE PRICE ASSOCIATES, INC. Bought 1.1 Million shares of Biogen